Modification of a Volume-Overload Heart Failure Model to Track Myocardial Remodeling and Device-Related Reverse Remodeling by Tuzun, Egemen et al.
International Scholarly Research Network
ISRN Cardiology
Volume 2011, Article ID 831062, 6 pages
doi:10.5402/2011/831062
Research Article
Modiﬁcation of a Volume-Overload Heart Failure Model to Track
MyocardialRemodelingandDevice-RelatedReverseRemodeling
EgemenTuzun,1,2 RogerBick,3 CihanKadipasaoglu,1 JeffreyL.Conger,1 BrianJ.Poindexter,3
Igor D. Gregoric,1 O. H. Frazier,1 Jeffrey A.Towbin,4 andBranislavRadovancevic1
1Cardiovascular Surgical Research Laboratories, Texas Heart Institute, Houston, TX 77225, USA
2Texas A&M Institute for Preclinical Studies, 800 Raymond Stotzer Pkwy, Ste 2060, College Station, TX 77843-4478, USA
3Department of Pathology, University of Texas Health Science Center, Houston, TX 77030-1501, USA
4Department of Pediatric Cardiology, Baylor College of Medicine, Houston, TX 77030, USA
Correspondence should be addressed to Egemen Tuzun, egemen.tuzun@tamu.edu
Received 4 March 2011; Accepted 2 May 2011
Academic Editor: M. Guazzi
Copyright © 2011 Egemen Tuzun et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. To provide an ovine model of ventricular remodeling and reverse remodeling by creating congestive heart failure (CHF)
and then treating it by implanting a left ventricular assist device (LVAD). Methods. We induced volume-overload heart failure in
2 sheep; 20 weeks later, we implanted an LVAD and assessed recovery 11 weeks thereafter. We examined changes in histologic
and hemodynamic data and levels of cellular markers of CHF. Results. After CHF induction, we found increases in LV end-
diastolic pressure, LV systolic and diastolic dimensions, wall thickness, left atrial diameter, and atrial natriuretic protein (ANP)
and endothelin-1 (ET-1) levels; β-adrenergic receptor (BAR) and dystrophin expression decreased markedly. Biopsies conﬁrmed
LV remodeling. After LVAD support, LV systolic and diastolic dimensions, wall thickness, and mass, and ANP and ET-1 levels
decreased. Histopathologic and hemodynamic markers improved, and BAR and dystrophin expression normalized. Conclusions.
We describe a successful sheep model for ventricular and reverse remodeling.
1.Introduction
Congestive heart failure (CHF) is characterized by an initial
cardiac insult, followed by a compensatory response that
results in ventricular remodeling. At the cellular level, CHF
involves myocyte hypertrophy, cell death, and replacement
ﬁbrosis. At the subcellular level, the disease causes loss
of myoﬁlaments, alterations in cytoskeletal proteins, and
adrenergic desensitization.
For the past 2 decades, the diagnosis of heart failure
has relied on noninvasive methods (physical examination,
chest roentgenography, electrocardiography, and echocar-
diography) and invasive tests [1] .V a r i o u sb i o m a r k e r sh a v e
also been used to diagnose heart failure with marginal
clinical utility. In patients with ischemic heart disease and
myocardial infarction, the following biomarkers have shown
varying levels of sensitivity in detecting heart failure: lactic
dehydrogenase, creatine kinase myocardial band (CKMB),
troponins T and I, C-reactive protein, norepinephrine,
endothelin-1 (ET-1), interleukin-6, tumor necrosis factor-α
(TNF-α), atrial natriuretic protein (ANP), B-type natriuretic
peptide, beta-adrenergic receptors (BARs), and angiotensin
II [2–12]. Another cellular marker of heart failure is
dystrophin, a protein that connects the extracellular matrix
with the sarcomere via actin. Dystrophin abnormalities
have been associated with heart failure caused by genetic
susceptibility and viral infection [13]. Treatment of CHF
with left ventricular assist devices (LVADs) can reverse the
ventricular remodeling associated with heart failure, and
this reversal is correlated with normalization of cellular
markers in myocytes [14, 15]. The present pilot study was
undertaken to provide an ovine experimental model for
creating CHF, then reversing this condition by implanting
an LVAD. We assessed the changes in immunohistochemical,
histopathologic, and hemodynamic parameters to verify the
occurrence and extent of the remodeling events in heart
failure development (remodeling) and subsequent LVAD-
assisted recovery (reverse remodeling).2 ISRN Cardiology
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Figure 1: (a) Normal ventriculogram obtained before creation of mitral regurgitation (MR). (b) After chordal disruption, the
ventriculogram shows 2nd- to 3rd-degree MR.
(a)
†
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Figure 2: (a) Biopsy specimen obtained at left ventricular assist device (LVAD) implantation, showing a loss of myoﬁlaments in the
perinuclear region (asterisk) and the presence of cytoplasmic vacuoles (arrows). (b) Biopsy specimen obtained after 11 weeks of LVAD
unloading, showing a reduced loss of myoﬁlaments, with fewer and smaller cytoplasmic vacuoles (arrow) and more and larger mitochondria
(dagger). Magniﬁcation ×2500; scale bar 2μM.
2.MaterialsandMethods
2.1. Animal Model. Two male Rambouillet sheep (54 ±
4kg) were used in this study. The animals received humane
care in compliance with the Principles of Laboratory Animal
Care (National Society of Medical Research) and the Guide
for the Care and Use of Laboratory Animals (National
InstitutesofHealthPublicationno.85-23,revised1996).Our
Institutional Animal Care and Use Committee approved the
protocol in advance.
To accurately mimic the clinical scenario of ventricular
remodeling in heart failure, we created a volume-overload
heart-failure model by destroying the chordae tendineae of
each sheep’s mitral valve. After 20 weeks, we implanted
a Levitronix CentriMag (Levitronix LLC, Waltham, Mass)
(1st case) and a HeartWare LVAD (HeartWare International,
Inc., Framingham, Massachusetts) (2nd case) to support the
animals. After 11 weeks of LVAD support, the sheep were
reexamined for evidence of myocardial recovery.
2.2. Operative Procedures
2.2.1. Anesthesia. We followed a standard institutional anes-
thesia protocol that has previously been described in detail
[16]. Each sheep was premedicated with glycopyrrolate
(0.02mg/kg) and xylazine (0.2–0.7mg/kg); both drugs were
administered intramuscularly. Intravenous ketamine (10–
20mg/kg) was administered to induce anesthesia. General
anesthesia was maintained with isoﬂurane (1–3%) in oxygen
(40–100%).
2.2.2. 1st Operation: Creation of Mitral Regurgitation (Base-
line). Transthoracic echocardiography was performed toISRN Cardiology 3
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Figure 3: Identiﬁcation of markers in heart failure and recovery.
The results are expressed as the mean and standard error for each
time point: before induction of heart failure (a), after induction
of heart failure (b), and after 11 weeks of LVAD support (c).
ANP: atrial natriuretic protein; BAR: β-adrenergic receptors; ET-1:
endothelin-1; DYS: dystrophin; FPD: ﬂuorescence pixel density.
obtain baseline measurements of the left and right ven-
tricular dimensions, left ventricular mass, ventricular wall
thickness, and valve function. The baseline left ventric-
ular end-diastolic pressure (LVEDP) was measured with
a micromanometer-tip pigtail catheter (Millar Mikro-Tip
Catheter; Millar Instruments, Houston, Tex) inserted via the
left carotid artery. After baseline hemodynamic measure-
ments were made, baseline endomyocardial biopsy speci-
mens were taken from the left ventricle via a transaortic
route. With the sheep in stable condition, a baseline left
ventriculogram was performed to assess mitral valve func-
tion. The pigtail catheter was removed, and a reusable biopsy
and retrieval forceps (Cook Urological Inc., Spencer, Idaho)
were introduced into the left ventricle. Under ﬂuoroscopic
guidance, this forceps was used to grasp and cut 1 or
more chordae tendineae upon forceful withdrawal, creating
severe MR (3+ to 4+ Seller’s grade [17]) (Figures 1(a)
and 1(b)). This condition was deﬁned by a high degree of
opaciﬁcation of the left atrium 2 beats after left ventricular
contrast injection. After creation of the MR, the left carotid
artery was repaired, and the sheep was allowed to recover.
This procedure has previously been described elsewhere
[18]. During the follow-up period, the sheep underwent
echocardiography every 2 weeks to detect volume-overload
heart failure.
2.2.3. 2nd Operation: Implantation of an LVAD (20th Week)
Levitronix CentriMag LVAD. The Levitronix CentriMag
LVAD is a sterile, single-use, disposable, and centrifugal
pump. The pump’s 32-mL priming volume minimizes
the wetted surface area and helps to limit the need for
intravenous ﬂuids during surgery. The pump inlet is on the
rotational axis of the rotor; the pump outlet is perpendicular
to the inlet and tangential to the outer diameter. Both
the inlet and outlet ports are standardized 3/8-inch barbed
connectors for easy application to standard medical-grade
3/8-inch tubing. The blood pump design is based on
magnetic-levitation motor-bearing technology that allows
pumpingwithoutmechanicalbearingsandseals.Thepump’s
rotor“ﬂoats”inarotatingmagneticﬁeldwithoutmechanical
contact, and an external compact digital signal processor
system allows precise regulation of the rotor’s speed. The
pump is designed to provide ﬂow in the range of 0.5 to
9.9L/min.
The drive console is a microprocessor-based system
that includes user interface keys which provide convenient
management points for pump operation; a 4-line alphanu-
meric display for showing the system status; alert and alarm
information;27-segmentdigitaldisplaysthatshowthepump
speed and blood ﬂow rate.
HeartWare LVAD. The HeartWare LVAD is described in
detail elsewhere [19]. Brieﬂy, the HeartWare LVAD is a small,
wearless, and centrifugal blood pump. It has a displaced
volume of just 45 cc, weighs 145g, and can deliver ﬂows of
up to 10L/min.
Implantation Technique. For implantation of the CentriMag
LVAD, anesthesia was induced routinely, and hemodynamic,
echocardiographic, and ﬂuoroscopic measurements were
repeated as were the endomyocardial biopsies. A left thora-
cotomy was then performed in the 5th intercostal space, and
the left ventricular apex and descending aorta were exposed
for inﬂow and outﬂow cannula placement, respectively. After
2 pledgeted, 2-0 braided polyester pursestring sutures were
placed on the left ventricular apex and descending aorta, 32F
inﬂow and 20F outﬂow cannulas were inserted into these
2 structures, respectively. The procedures were done on the
beating heart without cardiopulmonary bypass. After the
cannulas were tunneled outside the chest wall, they were
connected to a centrifugal CentriMag extracorporeal LVAD,
and ﬂow was initiated at 4L/min. Pump ﬂow was measured
throughout the study with a 10-mm ﬂow probe (Transonic
SystemsInc.,Ithaca,NewYork)ontheoutﬂowgraftcannula,
and unloading of the left ventricle was adjusted according to
that chamber’s size. Device ﬂow was maintained between 5
and 7L/min. The LVAD was secured to each sheep’s body
with a girth strap. Postoperatively, the animals were treated
the same as after the initial operation. Adjunctive esmolol
infusion and diuretics were used to control tachycardia
and peripheral vascular resistance/urine output, respectively.
The animals were given warfarin to keep the international
normalized ratio between 2.5 and 3.5.
The same anesthesia and postoperative protocols were
used for HeartWare implantation, which has been detailed
elsewhere [19].
2.2.4. 3rd Operation: Hemodynamic, Echocardiographic, and
Fluoroscopic Studies after 11 Weeks of LVAD Support (31st
Week). Eleven weeks after placing the LVAD, we remeasured
the hemodynamic, echocardiographic, and ﬂuoroscopic
variables and repeated the endomyocardial biopsies with the
sheep under general anesthesia.
2.3. Echocardiographic Assessment. Echocardiographic as-
sessment was performed according to the guidelines of the4 ISRN Cardiology
American Society of Echocardiography [20]b ya ne c h o c a r -
diologist using a Sonos 2000 ultrasound system (Hewlett-
Packard Co., Palo Alto, Calif) equipped with a 2.5-MHz
phased-array transducer.
2.4. Histopathologic Evaluation. Endomyocardial biopsies
were performed before MR creation (baseline), during the
2nd operation (week 20), and during the 3rd operation
(week 31) and were evaluated with transmission electron
microscopy. Macroscopic postexplant analyses of the pump
were also done after termination of the study.
2.5. Immunohistochemical Staining. β-adrenergic receptor,
ANP,andET-1levelswereselectedasmarkersofheartfailure
and were ﬂuorescently labeled. Fluorescence was quantiﬁed
as pixel densities of speciﬁc colors in split color images,
using Corel Draw (Corel Corporation, Ottawa, ON, Canada)
and Sigma Scan Pro software (Aspire Software International,
Leesburg, Va).
2.6. Quantiﬁcation of Dystrophin in Ventricular Biopsy Spec-
imens. Expression of dystrophin was quantiﬁed by Western
blotting of whole tissue lysates prepared from biopsy tissues.
Consequently, confocal immunoﬂuorescence was used to
obtain robust quantitative information about the number of
immunoreactive signals at discrete sites within the cell.
3. Results
3.1. Induction (Remodeling Phase) and Treatment (Reverse
Remodeling Phase) of Heart Failure. In both cases, com-
parison of hemodynamic, ﬂuoroscopic, echocardiographic,
histopathologic, and immunohistochemical data recorded
(1) during the 1st operation and (2) immediately before
pump implantation conﬁrmed the eﬀectiveness of the heart
failure induction protocol.
After the 2nd operation, both sheep recovered from
anesthesia without complications and were extubated within
the 1st postoperative hour. Eleven weeks after LVAD implan-
tation, they reached the scheduled endpoint without experi-
encing anorexia, infection, or a neurologic disorder.
3.2. Device Examination and Animal Necropsy. The explant-
ed pumps’ interior, inﬂow cannula, and outﬂow cannula
were completely free of thrombus. There was no evidence of
ischemia or infarction in any of the peripheral end organs
(brain, liver, spleen, and kidneys).
3.3. Hemodynamic Data. The mean LVEDP, which was 8 ±
2mmHg at baseline, increased to 16 ± 2mmHg immediately
afterchordaldisruption andto27 ±4mmHgduring the2nd
operation.After11weeksofLVADsupport,themeanLVEDP
measured 14 ± 2mmHg.
3.4. Fluoroscopic Data. After the mitral chordae tendineae
weredisrupted,leftventriculographyconﬁrmedthepresence
of 2nd- to 3rd-degree MR (Figures 1(a) and 1(b)). During
the 2nd operation, repeat ventriculography showed 4th-
degree MR and a dilated left atrium. After 11 weeks of LVAD
support, ventriculography revealed 4th-degree MR and a
dilated left atrium at a pump ﬂow of 5L/min in both sheep.
3.5. Echocardiographic Data. Table 1 shows the mean echo-
car diographic results obtained during the 1st operation
(after mitral chordal disruption), 2nd operation (LVAD
implantation), and 3rd operation (after 11 weeks of LVAD
support). The echocardiographic data demonstrate that
volume-overload heart failure was successfully created in
both animals, with a resulting increase in the left ventric-
ular diastolic dimension (LVDD), left ventricular systolic
dimension (LVSD), and left ventricular mass. After LVAD
support, the echocardiographic measurements improved,
with a substantial decrease in the LVDD, LVSD, and left
ventricular mass.
3.6.HistopathologicData. Transmissionelectronmicroscopy
of the myocardial biopsy specimens obtained during LVAD
placement (2nd operation) showed a 58 ± 5% loss of
myoﬁlaments in the perinuclear region; the presence of
cytoplasmic vacuoles >1.5μm in diameter decreased by
33 ± 4%comparedtobaselinebiopsyﬁndings(Figure 2(a)).
After 11 weeks of LVAD unloading, the percentage of
c e l l sw i t hm o d e r a t et os e v e r em y o ﬁ l a m e n tl o s sd e c r e a s e d
from 58 ± 5% (at LVAD implantation) to 18 ± 3%. The
percentage of cells with cytoplasmic vacuoles >1.5μmi n
diameter decreased from 33 ± 4% to 5 ± 2%. Cardiac
myocytes showed an increase in the number and size of their
mitochondria (Figure 2(b)).
3.7. Immunohistochemical Data. Compared to baseline val-
ues, there was a marked increase in the ﬂuorescence pixel
densityforANPandET-1alongwithareductioninBARand
dystrophin density (Figure 3), which is evidence of volume-
overload heart failure.
After 11 weeks of LVAD support, biopsy samples showed
a marked decrease in ﬂuorescence pixel density for ANP and
ET-1, along with an increase in BAR and dystrophin density
(Figure 3) which may be considered a sign of myocardial
reverse remodeling.
4. Discussion
In our pilot study, the left ventricular diastolic and systolic
dimensions increased with heart failure and decreased after
LVAD support, although baseline levels were not regained
after 11 weeks of LVAD support. The cardiac index and
left ventricular mass were elevated during heart failure and
returned to near baseline levels after 11 weeks of LVAD
support. Together, these results indicated the successful
development of heart failure in sheep after chordal disrup-
tion,followedbyrecoveryafterLVADsupport,asdetermined
by physical measurements and hemodynamic data.
We used an adult sheep model, primarily because of the
ease with which heart failure can be induced and subsequentISRN Cardiology 5
Table 1: Mean echocardiographic measurements obtained in each individual sheep during the 1st operation (after mitral chordal
disruption), 2nd operation (left ventricular assist device (LVAD) implantation), and 3rd operation (after 11 weeks of LVAD support).
Time LVDD (mm) LVSD (mm) IVS (mm) PW (mm) RVDD (mm) LA (mm) EF (%) LV mass (g)
Sheep 1
1st operation (baseline) 32 22 7 7 19 32 55 201
2nd operation (wk 20) 59 44 11 9 26 48 44 570
3rd operation (wk 31) 41 26 11 10 29 48 56 210
Sheep 2
1st operation (baseline) 36 26 9 9 25 36 65 233
2nd operation (wk 20) 68 50 13 11 30 56 50 610
3rd operation (wk 31) 45 30 13 12 35 56 64 236
EF: ejection fraction; IVS: interventricular septal thickness; LA: left atrial dimension; LV: left ventricular; LVDD: left ventricular diastolic dimension; LVSD:
left ventricular systolic dimension; PW: posterior wall thickness; RVDD: right ventricular diastolic dimension.
LVAD therapy can be applied in this model. Other funda-
mental advantages of the sheep are the animal’s size (which
allows placement of a human-sized LVAD), minimal growth
rate, ease of management, and hemodynamic similarities to
humans.Moreover, theability to performsequential biopsies
allowed us to monitor the progress of heart failure and
to correlate the extent of remodeling and its reversal with
ANP,ET-1,BAR,anddystrophinlevels.Becauseourvolume-
overload heart failure ovine model was not a previously
established one, biopsies to detect heart failure creation
(remodeling) and postimplant recovery timing (reverse
remodeling) were scheduled and performed according to the
guiding results of the echocardiographic follow-up data. The
echocardiographic ﬁndings of volume-overload heart failure
(such as ejection fraction, left atrial diameter, left ventricular
end-systolic and end-diastolic dimensions, ventricular mass
and thickness, etc.) and LVAD recovery correlated well with
the animal’s clinical picture and hemodynamics, so we also
scheduled LVAD implantation and support times according
to these echocardiographic results.
The changes in dystrophin expression in our pilot
study were consistent with the development of heart failure
and subsequent recovery after LVAD placement in humans
[14]. Because dystrophin has been demonstrated to play
a key role in linking the actin cytoskeletal networks and
the sarcolemmal dystrophin-associated protein complex,
the lack of dystrophin is associated with altered structure
and mechanical adherence of costameres to the underlying
cytoskeletal actin network, resulting in cardiomyopathy
[15]. Therefore, the possible fragility (disruption) of the
dystrophin-actin bonds may be important for tracking early
myocardial structural changes in remodeling and reverse
remodeling and for developing a more precise animal model
of heart failure to test the eﬃcacy of short- or long-term
LVAD support.
One of our study’s limitations was the lack of plasma
proﬁles of dystrophin levels, which may be used as a
predictive/clinical biomarker for left ventricular remodeling
related to LVAD use. Such plasma proﬁles will be a main
focus of our future studies involving a larger number
of animals. Moreover, the location of the outﬂow-graft
anastomosis may be considered another study limitation, as
it may not be the anastomotic site currently preferred for
most fully implantable LVAD outﬂow grafts.
5. Conclusion
In this pilot experimental study, we have demonstrated an
experimental animal model in which we created CHF in
2 adult sheep and subsequently reversed this condition by
implanting 2 diﬀerent centrifugal LVADs (1 device in each
animal). The degree of remodeling was indicated by the dis-
r u p t i o no fd y s t r o p h i ne x p r e s s i o n ,a sw e l la sh e m o d y n a m i c ,
echocardiographic, histologic, molecular, and clinical signs
of heart failure. The reversal of heart failure (myocardial
recovery),bymeansofmechanicalcirculatoryassistance,was
indicated by the normalization of dystrophin expression and
integrity. We believe that this technique for creating and
subsequently treating CHF with LVAD therapy may be useful
in future studies investigating the diagnosis and prevention
of CHF.
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